GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Infant Bacterial Therapeutics AB (OSTO:IBT B) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Jul. 24, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Infant Bacterial Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate is N/A.


Competitive Comparison of Infant Bacterial Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Infant Bacterial Therapeutics AB  (OSTO:IBT B) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.


Infant Bacterial Therapeutics AB Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines